Source:http://linkedlifedata.com/resource/pubmed/id/16799614
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2006-7-19
|
| pubmed:abstractText |
We explored the safety and efficacy of rituximab administered in combination with the standard transplant conditioning regimen of cyclophosphamide (Cy) 120 mg/kg and total body irradiation (TBI) 12 Gy for adult patients with acute lymphoblastic leukemia (ALL). Patients were eligible if their disease expressed CD20. Rituximab was administered at 375 mg/m2 weekly for four doses beginning on day -7 of the conditioning regimen. Graft-versus-host-disease (GVHD) prophylaxis consisted of tacrolimus and methotrexate. Thirty-five patients undergoing matched sibling (n = 23) or unrelated donor (n = 12) transplantation were studied, with a median age of 30 years (range 15-55 years). At 2 years, progression-free survival, treatment-related mortality, and overall survival were 30, 24, and 47%, respectively. There was no delay in engraftment or increased incidence of infection. The cumulative incidence of grade II-IV acute GVHD was 17%, and limited and extensive chronic GVHD was 43% at 2 years. The addition of rituximab to the standard Cy/TBI transplant conditioning regimen in ALL was safe and well tolerated, and there was a suggestion of decreased incidence of acute GVHD when compared to historically reported GVHD rates for this group of patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:ChamplinR ERE,
pubmed-author:CourielD RDR,
pubmed-author:GajewskiJ LJL,
pubmed-author:GiraltSS,
pubmed-author:HaC SCS,
pubmed-author:IppolitoEE,
pubmed-author:KebriaeiPP,
pubmed-author:KhouriI FIF,
pubmed-author:MaCC,
pubmed-author:QazilbashM HMH,
pubmed-author:SalibaR MRM,
pubmed-author:de LimaMM
|
| pubmed:issnType |
Print
|
| pubmed:volume |
38
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
203-9
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:16799614-Adolescent,
pubmed-meshheading:16799614-Adult,
pubmed-meshheading:16799614-Antibodies, Monoclonal,
pubmed-meshheading:16799614-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:16799614-Burkitt Lymphoma,
pubmed-meshheading:16799614-Chi-Square Distribution,
pubmed-meshheading:16799614-Female,
pubmed-meshheading:16799614-Graft vs Host Disease,
pubmed-meshheading:16799614-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16799614-Humans,
pubmed-meshheading:16799614-Immunologic Factors,
pubmed-meshheading:16799614-Middle Aged,
pubmed-meshheading:16799614-Precursor B-Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:16799614-Statistics, Nonparametric,
pubmed-meshheading:16799614-Survival Analysis,
pubmed-meshheading:16799614-Transplantation, Homologous,
pubmed-meshheading:16799614-Transplantation Conditioning,
pubmed-meshheading:16799614-Treatment Outcome
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia.
|
| pubmed:affiliation |
Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. pkebriae@mdanderson.org
|
| pubmed:publicationType |
Journal Article
|